Loading clinical trials...
Loading clinical trials...
A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.
Age
30 - 70 years
Sex
ALL
Healthy Volunteers
No
Miami Gardens, Florida, United States
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
dGd Research
San Antonio, Texas, United States
Start Date
February 1, 2009
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
May 17, 2013
44
ACTUAL participants
ITCA 650 (exenatide in DUROS)
DRUG
Lead Sponsor
Intarcia Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587